DOCSLIB.ORG

HBA Advisory Board Identifies Long-Term Strategic Opportunities

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HBA Advisory Board Identifies Long-Term Strategic Opportunities SEPTEMBER/OCTOBER 2008 THE THE NEWSLETTER OF THE HEALTHCARE BUSINESSWOMEN’S ASSOCIATION HBA Advisory Board Identifi es Long-Term Strategic Opportunities, Addresses Changing Healthcare Environment Lativia Ray-Alston HBA Director-at-Large, Special Recognition Programs e 2008 HBA Advisory Board meeting has provided the HBA Board of Directors with insights into issues of interest to both individual members and corporate partners as the organization continues to strive to be the premier catalyst for the leadership development of women in healthcare worldwide. Members of the HBA Advisory Board (left to right): LYNN O’CONNOR VOS, Grey Healthcare; ADRIANN SAX, Under the direction of Advi- King Pharmaceuticals; MERYL ZAUSNER, Novartis; PATTY MARTIN, Eli Lilly; PATRICIA DANZON, e Wharton School of Business; RENEE SELMAN, ETHICON; BARBARA PRITCHARD, Intermedica, Inc.; KATHY LUNDBERG, sory Board chair Alex Gorsky, Boston Scientifi c; WAYNE YETTER, Verispan; NANCY LARSEN, PROmedica Communications; PAUL FONTEYNE, Company Group Chairman Boehringer Ingelheim; LESA LARDIERI, Pfi zer; ALEX GORSKY, ETHICON; ELIZABETH MUTISYA, 2008 HBA and Worldwide Franchise President; CHARLOTTE SIBLEY, Shire; MARK MALLON, AstraZeneca; and KATHRYN O’FEE, GlaxoSmithKline. See the full list of HBA Advisory Board Members on page 8. Chairman, ETHICON, INC. a Johnson & Johnson Company, 19 industry leaders represent- care environment, evolving challenges HBA members face in ing a cross-section of healthcare disciplines convened for a full their careers and how to best equip HBA members for success. day to facilitate a deeper understanding of the changing health- turn to Advisory Board on page 3 IN THIS ISSUE 2 THE CEO’S CORNER Novartis Pharmaceuticals to Go for the Gold Take Home HBA ACE Award 3 Participate in Governance of the Novartis Pharmaceuticals Corporation’s Employee Resource Group will take home the HBA second annual HBA ACE Award for its Empowering Women to Impact Novartis (EWIN) 4 HOT TOPIC… and Women in Leadership (WIL) initiatives. Leadership in 2010 The HBA ACE Award was created by the HBA in 2007 to honor 6 FOCUS ON… one industry company for its Advancement, Commitment and Proper English in a txt-msg World Engagement on behalf of women’s careers in the healthcare 7 Call for WOTY Nominations industry. The fi rst recipient was Johnson & Johnson’s Women in Leadership initiative. 7 THE EDITOR’S NOTES Getting into Leadership So join your colleagues as we honor Novartis for its EWIN and WIL initiatives when the HBA presents the ACE Award during the November 6 Leadership Conference luncheon. 8 THE PRESIDENT’S FORUM Becoming a Great Leader HEALTHCAREHEALTHCARE BUSINESSWOMEN’S BUSINESSWOMEN’S ASSOCIATION ASSOCIATION | Required | Required Experience Experience for Healthy for Healthy Careers Careers | www.hbanet.org | www.hbanet.org 1 The HBAdvantage is published bimonthly for the members of the Healthcare Businesswomen’s Association, Go For the Gold 373 Route 46 West, Bldg. E, Suite 215, Fairfi eld, NJ 07004. Phone: (973) 575-0606 Fax: (973) 575-1445 E-mail: [email protected] Web: www.hbanet.org THE CEO’S CORNER Laurie Cooke, RPh EDITORINCHIEF Donna K. Ramer EDITORS Joanna Breitstein and Susan Youdovin Watching the Olympics amazed and inspired me. e spirited enthusiasm of the MANAGING EDITOR Joanne Tanzi cheering crowds, the collection of countries sharing the fi elds and China’s hercu- ART DIRECTOR DeborahAnne Chingas Sandke ADMINISTRATIVE COORDINATOR Lisa Kelly lean accomplishments to complete the necessary infrastructure for the Olympics Please send correspondence regarding The HBAdvantage off ered a magnifi cent display of global cooperation and achievement. to Joanne Tanzi at the above address. Of course, don’t let the spectacle fool you. For those few moments on screen, HBA STAFF CHIEF EXECUTIVE OFFICER Laurie Cooke, RPh the athletes endured years of discipline and focus to achieve their goal of partici- EXECUTIVE DIRECTOR Carol Davis-Grossman pating in the Olympics. And, of course, what you don’t see are the other parts of the DIRECTOR, CHAPTER DEVELOPMENT Mary-Margaret Armstrong puzzle: the coaches, mentors and judges that selected, trained and encouraged those DIRECTOR, CORPORATE DEVELOPMENT Marianne Fray athletes to go on and represent their countries. HBA BOARD OF DIRECTORS ere are some obvious parallels between the Olympics and our upcoming Annual Executive Committee Business Meeting. e purpose of the meeting—to be held this year on November 6 in PRESIDENT Elizabeth M. Mutisya, MD PRESIDENT-ELECT Ceci Zak, Vice President, Allergy, Chicago—is to discuss the year’s top accomplishments and present a slate of candidates sanofi -aventis FIRST VICE PRESIDENT Susan Torroella, CEO, to govern the HBA. And while there won’t be elaborate pyrotechnics or synchronized Columbia MedCom Group, Inc. choreography performed by thousands, the annual meeting does off er an Olympian SECOND VICE PRESIDENT Lori Ryan, Executive Director Business Planning & Analysis, Novartis opportunity for all members to be involved in the governance of the HBA as we show- Pharmaceuticals Corporation case the association’s fi nest athletes: the IMMEDIATE PAST PRESIDENT Cathy Kerzner, SVP & GM, Women’s Health Care BU, Wyeth ANNUAL BUSINESS MEETING highly qualifi ed women who will be part TREASURER Yvonne D’Amelio, Chief Financial of the 2009 Board of Directors. Offi cer & Principal, Vox Medica, Inc. QUICK FACTS SECRETARY Deborah Coogan Seltzer, Senior However, the most important role and Vice President, Pearson Partners International ▶ Date/Location: Thursday, November 6 in the fi nal determinant is you. It is you who Directors-at-Large Chicago during a break in the Leadership Susan Adler, Vice President, Commercial Analytics, will vote on these candidates as they “go Sepracor Inc. Conference. for the gold” and assume the most senior Violet B. Aldaia, Senior Vice President, BrandEdge ▶ Eve Dryer, President, Vox Medica Public Relations; Eligibility to Vote: Must be an HBA member HBA leadership positions. As a member, Principal and EVP, Vox Medica Healthcare as of Oct 1, 2008. Communications we need you to make your voice heard. Sheryl “Sherry” Fox, President, North America, ▶ Ballot: Board of Director o cers, open Once elected, the members of the board THE PLANNING SHOP international Arlene Kirsch, PhD, Vice President, Kaiser Team, Director-at-Large positions, two members are given the ultimate authority to oper- GlaxoSmithKline of the Nominating Committee. (Candidates ate the association within the structure Lativia Ray-Alston Leigh Ann Soltysiak Luzzi, Marketing Director, must be members in good standing of the sanctioned by our members. And, based Worldwide ETHICON, Johnson & Johnson HBA and meet stringent service criteria.) Leanne C. Wagner, Vice President, Commercial on our bylaws, you also will vote for two Diff erentiation Strategy, Wyeth ▶ Other Agenda Items: Proposed bylaws members of the Nominating Committee, Eileen Woods, Managing Partner, Agentive Sales & amendments or resolutions. Marketing Solutions which is empowered to bring qualified Director, Council of Presidents Karla Gonye ▶ Details: Will be mailed to all members in candidates to the membership. 2008 Non-Voting Director early October. If you were like me, you sat transfi xed Barbara Pritchard President, The Pritchard Group / Intermedica, Inc. ▶ in front of the television watching the Proxy: If you are unable to attend, you can CHAPTER/AFFILIATE PRESIDENTS proxy your vote by returning the form in Olympics. But the HBA Annual Business ATLANTA CHAPTER—Juliann Kaiser, President, your mailing. Meeting is the time for all of us to fl ex Kaiser Marketing Group BOSTON CHAPTER—Buket E. Grau, Strategic our muscles. Don’t sit at home and wait Marketing Manager, Stryker Development CHICAGO CHAPTER—Denise Kitchen, Vice President, to hear about it. Experience the HBA’s Human Resources, TAP Pharmaceutical Products Inc. leadership Olympics fi rst-hand. ere is no time like November 2008 to expand your EUROPE CHAPTER—Florence Manger, Xolair Global Brand Manager, Novartis AG leadership acumen and to exercise your right to vote for your HBA Leaders. See you GREATER PHILADELPHIA CHAPTER—Lee Ann Kimak, Senior Director, US & Pharmaceutical in Chicago! HBA Operations, Wyeth Pharmaceuticals INDIANA CHAPTER—Cheryl Beal Anderson, Director, US Regulatory Aff airs, Eli Lilly and Company, Inc. METRO CHAPTER—Kathleen Milligan, Senior Director, Global Marketing/Life Cycle Management, Plavix US, Bristol-Myers Squibb Company Expand Your Horizons at the MID-ATLANTIC CHAPTER—Chris Hoff man, MS, Principal, Hoff man Innovations OHIO AFFILIATE—Maureen Doyle-Scharff , MBA, 6th Annual FACME Director Medical Education Group, Pfi zer Inc RESEARCH TRIANGLE PARK CHAPTER—Alison Otstot, PhD, President, A2 Analytics SAN ANTONIO AFFILIATE—Deb Wells, President/ HBA LEADERSHIP CONFERENCE CEO, StrokeGuard, Inc. SAN FRANCISCO CHAPTER—Sharon Rundberg, Executive Vice President, Internal Resources, Dorland Global Corporation November 5-7, 2008 ST. LOUIS AFFILIATE—Beth Hackett, President, The Sage Consulting Group SOUTHERN CALIFORNIA CHAPTER—Heather Chicago Linehan, Vice President, BioQuest, LLC 2 The HBAdvantage | SEPTEMBER / OCTOBER 2008 | www.hbanet.org ©2008 Healthcare Businesswomen’s Association Participate in Governance of the HBA Deborah Seltzer Vice President, Pearson Partners International, and Secretary, HBA This year’s ANNUAL BUSINESS MEETING will be held: One of the most important responsibilities and opportunities an Thursday, November 6, 2008 HBA member has is to vote for the
Load more

Recommended publications
  • 2009: Turning the Corner
    data page 2009: Turning the corner Walter Yang Despite the shaky start to 2009, the biotech sector regained its financial Although initial public offerings showed signs of resuscitation (at least footing. Biotech indices were up, as were offerings and partnership mon- 13 more companies are now in the queue), follow-on financings came in ies. Excluding collaborations, the sector raised a total of $24.3 billion. above $6 billion—the second-best year over the past decade. Stock market performance Global biotech industry financing Although biotech indices were up ~16% last year, they underperformed The boost in partnership promises to US biotechs and follow-on financings other major indices. pushed industry funding to $61.3 billion, up 82% from 2008. 1,500 Swiss Market S&P 500 2009 36.9 10.0 5.1 2.2 6.0 0.9 1,400 NASDAQ Biotech Dow Jones 2008 20.0 3.2 5.3 3.1 1.9 0.1 1,300 NASDAQ BioCentury 100 2007 22.4 11.7 6.8 4.7 4.4 3.0 1,200 Partnering 2006 19.8 11.9 5.6 4.7 5.6 2.0 1,100 Year Debt and other Index 17.3 6.1 5.4 2.7 4.8 1.9 1,000 2005 Venture capital PIPEs 900 2004 10.9 8.8 5.3 2.9 3.3 2.6 Follow-ons 800 2003 8.9 9.1 4.0 2.2 3.9 0.5 IPOs 700 010203040506070 Amount raised ($ billions) 1/09 2/09 3/09 4/09 5/09 6/09 7/09 8/09 9/09 12/08 Month ending 10/09 11/09 12/09 Partnership figures are for deals involving a US company.
    [Show full text]
  • Johnson & Johnson
    JOHNSON & JOHNSON FORM 10-K (Annual Report) Filed 02/22/13 for the Period Ending 12/30/12 Address ONE JOHNSON & JOHNSON PLZ NEW BRUNSWICK, NJ 08933 Telephone 732-524-2455 CIK 0000200406 Symbol JNJ SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/12 http://www.edgar-online.com © Copyright 2013, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 30, 2012 Commission file number 1-3215 JOHNSON & JOHNSON (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State of incorporation) (I.R.S. Employer Identification No.) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (732) 524-0400 SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT Title of each class Name of each exchange on which registered Common Stock, Par Value $1.00 New York Stock Exchange Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Overview of Ftc Antitrust Actions in Pharmaceutical Services and Products
    OVERVIEW OF FTC ANTITRUST ACTIONS IN PHARMACEUTICAL SERVICES AND PRODUCTS Health Care Division Bureau of Competition Federal Trade Commission Washington D.C. 20580 Markus H. Meier Assistant Director Bradley S. Albert Deputy Assistant Director Saralisa C. Brau Deputy Assistant Director September 2009 TABLE OF CONTENTS Page I. INTRODUCTION. ........................................................... 1 II. CONDUCT INVOLVING PHARMACEUTICAL SERVICES AND PRODUCTS. 3 A. Monopolization. ...................................................... 3 B. Agreements Not to Compete. ............................................ 8 C. Agreements on Price or Price-Related Terms. 14 D. Agreements to Obstruct Innovative Forms of Health Care Delivery or Financing. 20 E. Illegal Tying and Other Arrangements. .................................... 20 III. PHARMACEUTICAL MERGERS. ........................................... 20 A. Horizontal Mergers Between Direct Competitors. 20 B. Potential Competition Mergers. ......................................... 44 C. Innovation Market Mergers. ............................................ 47 D. Vertical Mergers...................................................... 49 IV. INDUSTRY GUIDANCE STATEMENTS...................................... 50 A. Advisory Opinions. ................................................... 50 B. Citizen Petition to the Food and Drug Administration. 51 V. AMICUS BRIEFS. ......................................................... 51 VI. INDICES. ............................................................
    [Show full text]
  • SEC Form 10-K Annual Report
    e10vk 10-K 1 y80744e10vk.htm FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 3, 2010 Commission file number 1-3215 JOHNSON & JOHNSON (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State of incorporation) (I.R.S. Employer Identification No.) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (732) 524-0400 SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT Title of each class Name of each exchange on which registered Common Stock, Par Value $1.00 New York Stock Exchange Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes þ No o Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes o No þ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
    [Show full text]
  • 28 May 2009 Thomas E. Costa
    The Third International Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Thomas E. Costa 2828 MayMay 20092009 This presentation represents my own personal opinion and is not the official position of Bristol-Myers Squibb PhRMA Code 2009 • Updated in response to concerns of healthcare stakeholders • Reaffirms that interactions between pharmaceutical company representatives and healthcare professionals (HCPs) should: ¾ Inform HCPs about the benefits and risks of our products ¾ Provide scientific and educational information ¾ Obtain feedback and advice about our products through consultation with medical experts • The PhRMA Code is the new industry standard PhRMA Code Signatory Companies • Abbott • Eli Lilly and Company • Amgen, Inc. • Merck & Company, Inc. • Amylin Pharmaceuticals, Inc. • Millennium Pharmaceuticals, Inc. • Astellas US LLC • Novartis Pharmaceuticals • AstraZeneca LP Corporation • Bayer HealthCare • Novo Nordisk Inc. Pharmaceuticals • Otsuka America, Inc. • Boehringer Ingleheim • Ovation Pharmaceuticals, Inc. Pharmaceuticals, Inc. • Pfizer, Inc. • Bristol-Myers Squibb Company • Purdue Pharma LP • Cephalon, Inc. • sanofi-aventis US • Covidien Ltd. • Schering-Plough Corporation • Daiichi Sankyo, Inc. • Sepracor, Inc. • Eisai, Inc. • Signa-Tau Pharmaceuticals, Inc. • EMD Serono • Solstice Neurosciences, Inc. • Endo Pharmaceuticals, Inc. • Solvay Pharmaceuticals, Inc. • Genzyme Corporation • Takeda Pharmaceuticals North • GlaxoSmithKline America, Inc. • Hoffmann-La Roche, Inc. • Wyeth • Johnson and Johnson
    [Show full text]
  • Management Liability Focus Johnson & Johnson 1
    Insured Profile Report – Management Liability Focus Johnson_________________________________________________________________________ & Johnson Company Profile Credit Details Location 1 Johnson and Johnson Plz Overall Credit Risk High Risk New Brunswick, NJ www.jnj.com Number of Legal Derogatory 84 Company Type Public Items Liability Amount $322,285.00 Formerly Known As N/A Experian Intelliscore 2.57 SIC Code 2834 SIC Code Description Pharmaceutical Preparations Experian Intelliscore Percentile 2.00 % of companies score lower and have higher credit risk Established 1955 Experian Commercial IntelliscoreSM is an all-industry commercial model using business information to predict business risk. Its Sales (in millions) $65,030.00 predictiveness is among the best on the market today The objective of the Commercial Intelliscore Model is to predict seriously Employees 117,900 derogatory payment behavior. Possible score range from 0 to 100, where 0 is high risk and 100 is low risk Total OSHA Violations 18 -Liability Amount is the total dollar amount of debtor’s legal liability, OSHA is an arm of the Department of Labor that conducts inspections of company including accounts in collection, tax liens,judgments and/or bankruptcies facilities with the goal of preventing work-related injuries, illnesses and deaths. -The Number of Legal Derogatory items are the sum of Tax-Lien Worksites that do not meet health and/or safety standards at the time of inspection may Count, Bankruptcy,Judgment, Collection-Counter and UCC Derog receive an OSHA violation. Total FDA NDC Drugs 177 The total number of FDA Drugs filed in the FDA NDC Drug Database. Business Description Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field.
    [Show full text]
  • Lna 2006 Profiles J.Qxp
    1 | Advertising Age | June 26, 2006 SpecialSpecial ReportReport:100 Profiles LEADING NATIONAL ADVERTISERSSupplement SUPPLEMENT June 26, 2006 100 LEADING NATIONAL ADVERTISERS Profiles of the top 100 U.S. marketers in this 51st annual ranking INSIDE TOP 100 RANKING COMPANY PROFILES SPONSORED BY The nation’s leading marketers Lead marketing personnel, ranked by U.S. advertising brands, agencies, agency expenditures for 2005. contacts, as well as advertising Includes data from TNS Media spending by media and brand, Intelligence and Ad Age’s sales, earnings and more for proprietary estimates of the country’s 100 largest unmeasured spending. PAGE 8 advertisers PAGE 10 This document, and information contained therein, is the copyrighted property of Crain Communications Inc. and The Ad Age Group (© Copyright 2006) and is for your personal, non-commercial use only. You may not reproduce, display on a website, distribute, sell or republish this document, or information contained therein, without prior written consent of The Ad Age Group. Are proud to connect you with the leading CMOs See all the interviews at adage.com/point LAUNCHING JUNE 28 © 2006 Crain Communications Inc. www.adage.com 3 | Advertising Age | June 26, 2006 Special Report 100 LEADING NATIONAL ADVERTISERS SUPPLEMENT ABOUT THIS PROFILE EDITION THE 51ST ANNUAL 100 Leading National the Top 100 ($40.13 billion) and for all measured spending in 18 national media, Advertisers Report crowned acquisition- advertisers ($122.79 billion) in the U.S. Yellow Pages Association contributed ladened Procter & Gamble Co. as the top U.S. ad spending by ad category: This spending in Yellow Pages and TNS Marx leader, passing previous kingpen General chart (Page 6) breaks out 18 measured Promotion Intelligence provided free- Motors Corp.
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • Bestccoorporations
    Navoba BUY VETERAN CORPORATE GOVERNMENT FRANCHISE YOUR BIZ COMMUNITY best corporations HUGE CORPORATE for vETERAN-OWNED By Matthew Pavelek CONTRACTING n 1999, the veteran-owned of their way to use VOBs. business movement took In 2007, approximately 10 a giant leap forward with percent of Fortune 1000 companies legislation requiring the sought veteran-owned suppliers. Ifederal government to recognize Through NaVOBA’s efforts, that vetrepreneurs and setting a mandate number has grown by more than OPPORTUNITIES to buy from businesses owned 60 percent. Today, more than 160 by service-disabled veterans. In Fortune 1000 companies maintain 2005, NaVOBA launched Veterans programs designed to use VOBs as Business Journal to bring the VOB preferred vendors in their supplier movement to corporate America. diversity eff orts. While the federal government is Retail colossus Walmart, FOR the world’s single largest purchaser consumer products behemoth of goods and services, the potential Proctor and Gamble, and innovative for vetrepreneurs selling to all of tech giant Apple, Inc. all buy veteran corporate America dwarfs the federal because it’s good business. Johnson opportunity. & Johnson, earning a place among YOUR BUSINESS Unlike the federal government NaVOBA’s Best 10 Corporations for and its prime contractors, many Veteran-Owned Businesses for 2011 states, and some local and municipal and 2012, provides further evidence governments, corporate America is that the VOB movement is advancing NaVOBA is proud to honor the 10 Best Corporationsporations not mandated by law to use veteran- well beyond the beltway. for Veteran-Owned Businesses for 2012. owned suppliers. Just like any Earning the honor as one of business, large corporations exist to NaVOBA’s 10 Best Corporations for turn a profi t.
    [Show full text]
  • Caring for the World . . .One Person at a Time™ Inspires and Unites the People of Johnson & Johnson
    OUR CARING TRANSFORMS 2007 Annual Report Caring for the world . .one person at a time™ inspires and unites the people of Johnson & Johnson. We embrace research and science—bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. The people in our more than 250 companies come to work each day inspired by their personal knowledge that their caring transforms people’s lives . one person at a time. On the following pages, we invite you to see for yourself. Our Caring Transforms ON THE COVER Johnson & Johnson is founding sponsor and continues to support Safe Kids Worldwide®. For 20 years the organization has grown, now teaching prevention as a way to save children’s lives in 17 countries around the world. In Brazil, Nayra Yara da Paz de Jesus carefully washes her hands, a safe, healthy habit she and other children are learning from a local Safe Kids® program. Find out more in our story on page 22. C H A I R M A N ’ S L E T T E R To Our Shareholders Caring for the health and well-being of people throughout the world is an extraordinary business. It is a business where people are passionate about their work, because it matters. It matters to their families, to their communities and to the world. It is a business filled with tremendous opportunity for leadership and growth in the 21st century; a business where unmet needs still abound and where people around the world WILLIAM C.
    [Show full text]
  • Why Are Some Generic Drugs Skyrocketing in Price? Hearing Committee on Health, Education, Labor, and Pensions United States Sena
    S. HRG. 113–859 WHY ARE SOME GENERIC DRUGS SKYROCKETING IN PRICE? HEARING BEFORE THE SUBCOMMITTEE ON PRIMARY HEALTH AND AGING OF THE COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS UNITED STATES SENATE ONE HUNDRED THIRTEENTH CONGRESS SECOND SESSION ON EXAMINING THE PRICING OF GENERIC DRUGS NOVEMBER 20, 2014 Printed for the use of the Committee on Health, Education, Labor, and Pensions ( Available via the World Wide Web: http://www.gpo.gov/fdsys/ U.S. GOVERNMENT PUBLISHING OFFICE 24–459 PDF WASHINGTON : 2017 For sale by the Superintendent of Documents, U.S. Government Publishing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2104 Mail: Stop IDCC, Washington, DC 20402–0001 VerDate Nov 24 2008 13:32 May 19, 2017 Jkt 000000 PO 00000 Frm 00001 Fmt 5011 Sfmt 5011 S:\DOCS\24459.TXT DENISE HELPN-003 with DISTILLER COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS TOM HARKIN, Iowa, Chairman BARBARA A. MIKULSKI, Maryland LAMAR ALEXANDER, Tennessee PATTY MURRAY, Washington MICHAEL B. ENZI, Wyoming BERNARD SANDERS (I), Vermont RICHARD BURR, North Carolina ROBERT P. CASEY, JR., Pennsylvania JOHNNY ISAKSON, Georgia KAY R. HAGAN, North Carolina RAND PAUL, Kentucky AL FRANKEN, Minnesota ORRIN G. HATCH, Utah MICHAEL F. BENNET, Colorado PAT ROBERTS, Kansas SHELDON WHITEHOUSE, Rhode Island LISA MURKOWSKI, Alaska TAMMY BALDWIN, Wisconsin MARK KIRK, Illinois CHRISTOPHER S. MURPHY, Connecticut TIM SCOTT, South Carolina ELIZABETH WARREN, Massachusetts DEREK MILLER, Staff Director LAUREN MCFERRAN, Deputy Staff Director and Chief Counsel DAVID P. CLEARY, Republican Staff Director SUBCOMMITTEE ON PRIMARY HEALTH AND AGING BERNARD SANDERS, Vermont, Chairman BARBARA A.
    [Show full text]
  • The Leading Source of Diabetes Business News It's Complicated
    The Leading Source of Diabetes Business News It’s Complicated January/February 2011 • No. 105 The diabetes business used to be fairly straightforward. It’s a lot more complicated now, but that’s not a bad thing. Take insulin. After it was commercialized in the early 1920s, the goal was clear: sell more insulin. But look at today’s three major insulin makers: Eli Lilly, sanofi-aventis, and Novo Nordisk. For all three, to be sure, insulin is still preeminent. The diabetes divisions of Novo Nordisk and Lilly draw most of their revenue from human insulin and rapid-acting analogs, while sanofi-aventis’ blockbuster basal analog Lantus, as well as its mealtime insulins, continue to drive the bottom line. But all three companies have also developed (or are developing) GLP-1 analogs, Lilly has invested in oral drugs for type 2 diabetes (most recently through a major partnership with Boehringer Ingelheim), and the companies are also developing new therapeutic approaches for different stages of disease progression. The evolution of the insulin makers reflects broader industry trends. As our understanding of diabetes has expanded – and we dig deeper into the molecular complexities of the disease – it’s clear that single- focus large companies can no longer prosper. Ours is an era of individualized treatment that mixes and matches different drugs and technologies that try to meet the unique needs of every person with diabetes. Toward that end, companies are forming partnerships to find complementary therapies and development efforts that will create
    [Show full text]